June 26, 2008

Duska Therapeutics Obtains Standard & Poor's Listing

June 11, 2008

Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins

June 9, 2008

Duska Therapeutics Retains Redington for Investor Relations

May 14, 2008

Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals

April 25, 2008

Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)

April 15, 2008

Duska Therapeutics Sets Annual Meeting of Shareholders for June 27

April 2, 2008

Professor Riccardo Polosa Joins Duska Therapeutics' Scientific Advisory Board

March 11, 2008

Duska Therapeutics Plans Meeting with the FDA on ATPace

February 20, 2008

Duska Therapeutics to Present At Winter Global Equities Conference

February 7, 2008

Study Shows ATP Improves Motility of Sperm From Infertile Males

January 29, 2008

Duska Therapeutics Completes Corporate Relocation to La Jolla

November 13, 2007 

Duska Therapeutics CEO Television Interview 

November 1, 2007 

Duska Therapeutics, Inc. Announces Engagement of RedChip Companies, Inc. to Lead Public and Investor Relations

October 31, 2007   

Duska Therapeutics Appoints Dr. Alan J.Tuchman to the Board of Directors

October 18, 2007    

Duska Therapeutics Appoints Shepard Goldberg and Steven Dinh as Board Directors

October 11, 2007    

Duska Therapeutics Appoints H. David Coherd to the Board of Directors

October 3, 2007      

Duska Therapeutics Names Dr. James S. Kuo as Chief Executive Officer

October 1, 2007      

Duska Therapeutics Completes $5.75 Million Private Equity Financing